8-K

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION


                             Washington, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT


     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): April 22, 2005


                       PROTEIN POLYMER TECHNOLOGIES, INC.
             (Exact name of registrant as specified in its charter)



            Delaware                       0-19724               33-0311631
- -----------------------------------  -------------------  ----------------------
 (State or other jurisdiction of         (Commission           (IRS Employer
  incorporation or organization)         File Number)        Identification No.)



    10655 Sorrento Valley Road, San Diego, California               92121
- ---------------------------------------------------------  ---------------------
         (Address of principal executive offices)                 (Zip Code)



    Registrant's telephone number, including area code:  (858) 558-6064
                                                         -----------------------

                                 Not Applicable
 -------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)


================================================================================





Item 1.01.  Entry into a Material Definitive Agreement.

                  On April 22, 2005, at a meeting of the Board of Directors, the
Board of Directors resolved that Mr. William N. Plamondon III, the Registrant's
recently appointed Chief Executive Officer, would receive a warrant entitling
him to purchase an aggregate of 2,000,000 shares of the Registrant's common
stock at an exercise price equal to the market price of the Registrant's common
stock at the close of the market on the date of the grant, $0.67 per share. The
warrants are immediately exercisable and expire three years after the date of
the grant.

Item 5.02. Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.


         At the same meeting as described in Item 1.01 to this Current Report on
Form 8-K, the Board of Directors of the Registrant elected James B. McCarthy to
the Registrant's Board. Mr. McCarthy was appointed at the same meeting to serve
as a member of the Stock Option and Compensation Committee of Board of
Directors.

         On April 25, 2005, the Registrant issued a press release announcing the
election. A copy of the press release is filed as Exhibit 99.1 to this Current
Report on Form 8-K.

Item 9.01.  Financial Statements and Exhibits.

         (c) Exhibits.

                  99.1       Press Release of Protein Polymer Technologies, Inc.
                             dated April 25, 2005





                                    SIGNATURE

                  Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                                     PROTEIN POLYMER TECHNOLOGIES, INC.,
                                     a Delaware corporation


Date: April 28, 2005                 By: /s/ J. Thomas Parmeter
                                         ---------------------------------------
                                          J. Thomas Parmeter
                                          Chairman of the Board





                                  EXHIBIT INDEX

Exhibit No.                Description
- -----------                -----------

99.1                         Press Release of Protein Polymer Technologies, Inc.
                             dated April 25, 2005

EX-99

                                                                    Exhibit 99.1


                                                           FOR IMMEDIATE RELEASE
MEDIA CONTACT:
Erin Davis
Director of Communications and Investor Relations
(858)558-6064 x120
edavis@ppti.com

              PROTEIN POLYMER TECHNOLOGIES NAMES JAMES B. MCCARTHY
                              TO BOARD OF DIRECTORS


                  SAN DIEGO, April 25, 2005 -- Protein Polymer Technologies,
Inc. (OTC BB: PPTI), announced today that James B. McCarthy, M.B.A., J.D. has
been elected to its Board of Directors. Having recently selected a new CEO, PPTI
is expanding the Board of Directors.

                  "James McCarthy brings over 30 years of global experience in
the healthcare, medical device, and biotech manufacturing fields to our
company," said William N. Plamondon, PPTI's newly appointed CEO. "His expertise
in planning and analysis will prove to be a great asset to our Board."

                  McCarthy is Chairman and Chief Executive Officer of Gemini
Consulting Group, Inc., Oak Brook, IL., a company specializing in the
development of hospitals and specialty medical facilities in both the U.S. and
overseas. He has also held senior management positions for a Chicago-based
health care consulting company, a medical device manufacturing company, and the
Medical Products Division of 3M Company. McCarthy has a BA from the University
of Notre Dame, a J.D. from Loyola University School of Law, and an MBA from the
Keller Graduate School of Management. He sits on several boards including
Wintrust Financial Corporation, Lake Forest, IL. (NASDAQ, WTFC), and Sirigen,
Inc., Santa Barbara, CA. "I am delighted to be joining the Board of Protein
Polymer Technologies", said McCarthy. "I look forward to working with the Board
and Management on the expansion and ongoing development of the company's
exciting technologies and products."

                  Protein Polymer Technologies, Inc., is a San Diego-based
company focused on developing products to improve medical and surgical outcomes.
From its inception in 1988, PPTI has been a pioneer in protein design and
synthesis, creating an extensive portfolio of proprietary biomaterials for use
in the development of bioactive devices. These genetically engineered
biomaterials are high molecular weight proteins, processed into products with
physical and biological characteristics tailored to specific clinical
performance requirements. Targeted products include urethral bulking agents for
the treatment of stress urinary incontinence, dermal augmentation products for
cosmetic and reconstructive surgery, surgical adhesives and sealants, scaffolds
for wound healing and tissue engineering, and depots for local drug delivery. To
date, PPTI has been issued twenty-six U.S. Patents on its core technology with
corresponding issued and pending patents in key international markets.





                  This press release contains forward-looking statements that
are based on management's views and expectations. Actual results could differ
materially from those expressed here; further, the Company is not obligated to
comment specifically on those differences. Risks associated with the Company's
activities include raising adequate capital to continue operations, scientific
and clinical product development uncertainties, competitive products and
approaches, continuing collaborative partnership interest and funding,
regulatory testing and approvals, and manufacturing scale-up. The reader is
encouraged to refer to the Company's 2004 Annual Report on Form 10-KSB, and
other recent filings with the Securities and Exchange Commission, copies of
which are available from the Company, to further ascertain the risks associated
with the above statements.